# Pontifax

> Pontifax is a VC fund in Herzliya backing Biotechnology and Health Care. See 117 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Herzliya, Israel
- Total investments: 117
- Last investment: Jul 2026
- Lead investor: 24%
- Fund size: $14M
- Last fund: Apr 2020
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/pontifax-venture-capital?trk=company_logo
- Website: http://www.pontifax.com

Pontifax is a healthcare-dedicated venture capital firm.The fund focuses on innovative bio-pharma opportunities.

## Contacts

5 contacts available for Pontifax. Shizune tracks 4 team members at Pontifax. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/pontifax?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $6.3M–$110M |
| Series B | $20M–$130M |
| Series C | $12M–$101M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 57 | 49% |
| Health Care | 46 | 39% |
| Pharmaceutical | 22 | 19% |
| Therapeutics | 21 | 18% |
| Medical | 20 | 17% |

30 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 29 | 25% |
| Series B | 24 | 21% |
| Series C | 18 | 15% |
| Funding Round | 11 | 9% |
| Post-IPO Equity | 6 | 5% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 31 | 26% |
| Israel | 24 | 21% |
| France | 7 | 6% |
| The Netherlands | 3 | 3% |
| Belgium | 2 | 2% |

10 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Ohad Hammer | Partner | 19 | https://shizune.co/investors/profile/ohad-hammer |
| Ran Nussbaum | Managing Partner and Co-Founder | 10 | https://shizune.co/investors/profile/ran-nussbaum |
| Tomer Kariv | Co-Founder and Chief Executive Officer | 7 | https://shizune.co/investors/profile/tomer-kariv |
| Momi Karako | Partner | 1 | https://shizune.co/investors/profile/momi-karako |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Crystalys Therapeutics | Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout. | $130M | Series B | Jul 22, 2026 |  |
| ADCendo | ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $75M | Series C | Apr 14, 2026 |  |
| Adcytherix | Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC) to treat diseases with a high unmet need, including cancer. | $122.8M | Series A | Oct 16, 2025 |  |
| Adcytherix | Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC) to treat diseases with a high unmet need, including cancer. | $122.8M | Series A | Oct 16, 2025 |  |
| Step Pharma | Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe. | $44.3M | Series C | Oct 15, 2025 |  |
| Crystalys Therapeutics | Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout. | $205M | Series A | Sep 30, 2025 |  |
| Kamari Pharma | Kamari Pharma develops innovative treatments for unmet needs and rare diseases in dermatology. | $23M | Series A | Jun 03, 2025 |  |
| Kamari Pharma | Kamari Pharma develops innovative treatments for unmet needs and rare diseases in dermatology. | $23M | Series A | Jun 03, 2025 |  |
| Abcuro | Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivovalidation in diseased tissue has uncovered new approaches to target key compartments of the immune system.The company was incorporated in 2015 and is based in Newton, Massachusetts. | $200M | Series C | Feb 12, 2025 |  |
| Lutris Pharma | Lutris Pharma develops drugs to improve anti-cancer therapy effectiveness. The company develops the topical B-Raf inhibitor LUT014, a proprietary small molecule that allows administration of epidermal growth factor receptor (EGFR) inhibitors to patients without the interruptions caused by typical cutaneous side effects.Lutris Pharma wasestablished in 2015 and is based in Tel Aviv-yafo, Israel. | $30M | Venture - Series Unknown | Jan 28, 2025 |  |

10 of 117 investments shown.

## Co-investors
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 27 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 22 deals together
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 15 deals together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 12 deals together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 11 deals together
- [Quark Venture](https://shizune.co/investors/profile/quark-venture) — VC Fund, 10 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [OurCrowd](https://shizune.co/investors/profile/ourcrowd) — VC Fund
- [Entrée Capital](https://shizune.co/investors/profile/entree-capital) — VC Fund
- [Pitango VC](https://shizune.co/investors/profile/pitango-venture-capital) — VC Fund

## Featured in investor lists
- [Health Care VC Funds](https://shizune.co/investors/health-care-vc-funds)
- [Biotech Investors](https://shizune.co/investors/biotech-investors)
- [Biotech VC Funds](https://shizune.co/investors/biotech-vc-funds)
- [All Investors in Israel](https://shizune.co/investors/investors-israel)
- [All VC Funds in Israel](https://shizune.co/investors/vc-funds-israel)
- [Health Care Investors in Middle East](https://shizune.co/investors/health-care-investors-middle-east)

## FAQ

### What does Pontifax invest in?

Pontifax invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 117 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Pontifax's check size?

Pontifax typically joins rounds of $6.3M–$110M at Series A, $20M–$130M at Series B and $12M–$101M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Pontifax participates in.

### How do I contact Pontifax?

Public channels for Pontifax include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Pontifax?

The team at Pontifax includes Ohad Hammer (Partner), Ran Nussbaum (Managing Partner and Co-Founder) and Tomer Kariv (Co-Founder and Chief Executive Officer). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co